Details:

Alternative Title:
Emerg Infect Dis
Personal Author:
Tan, Emily L.C.; Ooi, Eng Eong; Lin, Chin-Yo; Tan, Hwee Cheng; Ling, Ai Ee; ... More +
Tan, Emily L.C.; Ooi, Eng Eong; Lin, Chin-Yo; Tan, Hwee Cheng; Ling, Ai Ee; Lim, Bing; Stanton, Lawrence W.; Less -
Description:
Severe acute respiratory syndrome (SARS) is an infectious disease caused by a newly identified human coronavirus (SARS-CoV). Currently, no effective drug exists to treat SARS-CoV infection. In this study, we investigated whether a panel of commercially available antiviral drugs exhibit in vitro anti-SARS-CoV activity. A drug-screening assay that scores for virus-induced cytopathic effects on cultured cells was used. Tested were 19 clinically approved compounds from several major antiviral pharmacologic classes: nucleoside analogs, interferons, protease inhibitors, reverse transcriptase inhibitors, and neuraminidase inhibitors. Complete inhibition of cytopathic effects of SARS-CoV in culture was observed for interferon subtypes, b-1b, a-n1, a-n3, and human leukocyte interferon a. These findings support clinical testing of approved interferons for the treatment of SARS.
Subject:
[+]
Agents
Antiviral
Antiviral Agents
Antiviral Drugs
Antivirals
Coronavirus Infection
Dose-Response Relationship, Drug
Humans
In Vitro
Research
SARS Virus
Severe Acute Respiratory Syndrome
Antiviral Agents
SARS Virus

Source:
Emerg Infect Dis. 10(4):581-586.;
Document Type:
Journal Article;
Collection(s):
Emerging Infectious Diseases
Main Document Checksum:
[+]
urn:sha256:a3b49ce2f9c4a9040050342faec537ec7cdd8ecc420c8504c8cc47e5729c324e
File Type:

Supporting Files

• 	03-0458-F1.gif	gif
  	03-0458-F1.jpg	jpeg
  	03-0458-F2.gif	gif
  	03-0458-F2.jpg	jpeg
  	03-0458.nxml	txt
  	license.txt	txt

More +